Integrating network pharmacology, molecular docking and experimental verification to reveal the mechanism of artesunate in inhibiting choroidal melanoma

Qingyue Ma, Yichong Liu, Qian Zhang, Wen-dan Yi, Ying Sun, Xiaodi Gao, Xintong Zhao, Haowen Wang, Ke Lei, Wenjuan LuoFrontiers in Pharmacology 2024 · DOI

TL;DR

This study investigates the anti-cancer potential of artesunate (ART) against choroidal melanoma (CM), a rare but aggressive eye cancer. By combining computational methods (network pharmacology and molecular docking) with experimental validation, the researchers identified key molecular targets and pathways through which ART inhibits CM cell growth, induces apoptosis, and promotes cell cycle arrest.

What Problem Does This Paper Address?

Choroidal melanoma (CM) is a serious ocular malignancy with a poor prognosis and limited treatment options. Current therapies like radiation and surgery often lead to vision loss or enucleation, and their overall effectiveness is suboptimal. There's a critical need for novel therapeutic strategies to combat CM. Artesunate (ART), a derivative of artemisinin, has shown promise in various cancer types, but its specific mechanisms against CM remain largely unexplored. This paper aims to elucidate these mechanisms, paving the way for potential new treatments.

Methods

The researchers employed a multi-pronged approach:

  • Network Pharmacology: This computational technique was used to identify potential drug targets of ART and disease-related genes in CM. By analyzing the overlap between these two sets, they pinpointed key intersecting genes. Protein-protein interaction (PPI) networks were constructed and analyzed to identify core targets. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed to understand the biological processes and pathways involved.
  • Molecular Docking: This method simulated the binding interactions between ART and the identified core targets. It helps predict the binding affinity and how strongly ART might interact with these molecules.
  • Experimental Validation (In Vitro):
    • CCK-8 assay: To assess cell viability and determine the IC50 (concentration that inhibits viability by 50%).
  • Colony formation assay: To evaluate the clonogenic capacity (ability to form colonies) of CM cells.
  • Cell migration assay: To measure the effect of ART on CM cell migration.
  • Apoptosis assay (Annexin V-FITC/PI): To quantify the percentage of apoptotic cells.
  • Cell cycle analysis (flow cytometry): To determine the distribution of cells in different phases of the cell cycle.
  • ROS measurement (DCFH-DA probe): To assess intracellular reactive oxygen species (ROS) levels.
  • Western Blot (WB) assays: To analyze the expression levels of key proteins involved in identified pathways (e.g., PI3K/AKT/mTOR, p53, NRF2/HO-1).
  • Experimental Validation (In Vivo):
    • Subcutaneous xenograft tumor model: ART was administered to nude mice bearing CM tumors to evaluate its effect on tumor growth and weight.
  • Immunohistochemistry (IHC): To assess the expression of proliferation markers (Ki67) in tumor tissues.

Datasets

  • Drug Target Databases: PubChem, Swiss Target Prediction, Traditional Chinese Medicine Systems Pharmacology (TCMSP).
  • Disease Target Databases: Online Mendelian Inheritance in Man (OMIM), GeneCards, DisGeNET.
  • Protein Databases: NCBI, UniProt, Protein Data Bank (PDB).
  • Cell Lines: Human CM cell lines (C918, MUM2B, OMM2.3) and ARPE-19 (normal retinal pigment epithelium cell line).

Key Insights and Ideas

  • ART as a Multi-Target Agent: The study strongly suggests ART doesn't act on a single target but influences multiple pathways crucial for CM progression. This multi-targeting approach is often more effective against complex diseases like cancer.
  • Synergy of Computational and Experimental Approaches: The paper highlights the power of integrating computational predictions (network pharmacology, molecular docking) with experimental validation. This allows for efficient identification of promising therapeutic avenues and subsequent confirmation.
  • ART's Impact on Key Cancer Hallmarks: ART appears to tackle several hallmarks of cancer, including proliferation, migration, and resistance to apoptosis, by modulating specific signaling pathways.
  • ART's Potential for Lower Toxicity: The IC50 of ART in normal retinal cells (ARPE-19) was significantly higher than in CM cells, suggesting a potential therapeutic window with lower toxicity to healthy ocular tissues.

Key Results

  • Identification of 48 Common Targets: Network pharmacology identified 48 intersecting genes between ART targets and CM-related genes.
  • Core Pathways Identified: Key pathways implicated in ART's anti-CM effects include "Pathways in cancer," "Apoptosis," "PI3K/AKT signaling pathway," and "p53 signaling pathway."
  • Molecular Docking Confirmation: ART showed strong binding affinity (binding energy < -5 kcal/mol) with several core targets, including PIK3CA, MDM2, CASP3, and SRC.
  • In Vitro Efficacy: ART significantly inhibited CM cell proliferation, colony formation, and migration in a concentration-dependent manner.
  • Apoptosis Induction: ART treatment led to a significant increase in apoptosis in CM cells.
  • Cell Cycle Arrest: ART induced G0/G1 phase arrest in CM cells, accompanied by decreased expression of Cyclin D1, Cyclin E1, CDK2, and CDK4.
  • ROS Production: ART significantly increased intracellular ROS levels, which was partially reversed by the ROS scavenger NAC.
  • In Vivo Tumor Inhibition: ART treatment significantly reduced tumor volume and weight in a subcutaneous xenograft model in nude mice, with no significant impact on body weight.
  • Ki67 Reduction: IHC analysis showed a significant decrease in Ki67 expression in ART-treated tumors, indicating reduced proliferation.

Limitations and Future Work

  • Limited Scope of In Vivo Study: The in vivo study focused on one cell line (C918) and a single ART dosage. Future work could explore different cell lines and dosage regimens.
  • Further Mechanistic Elucidation: While key pathways are identified, the study suggests further research is needed to fully understand ART's role in apoptosis via caspase pathways and its impact on CM migration through MMPs.
  • Oxeiptosis as a Potential Mechanism: The discussion hints at oxeiptosis (a ROS-induced, caspase-independent cell death) as a possible mechanism, which warrants further investigation.
  • Clinical Translation: While promising, these findings are preclinical. Further studies are needed to assess ART's efficacy and safety in clinical trials for CM.

Summary updated

Abstract

This study, making the initial exploration, illustrated through network pharmacology combined with molecular docking and <i>in vitro</i>/<i>in vivo</i> assays, confirmed that ART exerted potential anti-cancer effects on CM by promoting apoptosis, inducing cell cycle arrest and increasing intracellular levels of ROS. These findings suggested that ART held significant therapeutic potential for CM.
BibTeX
@inproceedings{ma2024integrating,
  author = {Qingyue Ma and Yichong Liu and Qian Zhang and Wen-dan Yi and Ying Sun and Xiaodi Gao and Xintong Zhao and Haowen Wang and Ke Lei and Wenjuan Luo},
  title = {{Integrating network pharmacology, molecular docking and experimental verification to reveal the mechanism of artesunate in inhibiting choroidal melanoma}},
  booktitle = {Frontiers in Pharmacology},
  year = {2024},
  doi = {10.3389/fphar.2024.1448381},
}
Figure